title: From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience.
abstract: Molecular selection has led to the successful use of novel tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancers (NSCLCs). For instance, mutations inEGFRand translocations and fusions inALKrender tumor cells sensitive to some TKIs, leading to substantial clinical benefits. Molecular testing such as DNA sequencing or fragment analysis following PCR, and evaluation of copy number and gene positioning by FISH, have been developed and used clinically to identify mutations/fusions. Meanwhile, TKIs to target actionable mutations/fusions in several other oncogenes are being evaluated. High-throughput sequencing can provide therapy-predictive information as well as identify novel targetable genomic alterations. In this article, we report our experience enabling single-gene testing, and our evolution to panel-based next-generation sequencing.
authors.affiliation: Departments of Internal Medicine & Pathology, The Ohio State University, 320 W, 10th Avenue, Columbus, OH 43210, USA ; Comprehensive Cancer Center, The Ohio State University, 320 W, 10th Avenue, Columbus, OH 43210, USA.
authors.forename: Weiqiang
authors.initials: W
authors.lastname: Zhao
authors.affiliation: Departments of Internal Medicine & Pathology, The Ohio State University, 320 W, 10th Avenue, Columbus, OH 43210, USA ; Comprehensive Cancer Center, The Ohio State University, 320 W, 10th Avenue, Columbus, OH 43210, USA.
authors.forename: Senthilkumar
authors.initials: S
authors.lastname: Damodaran
authors.affiliation: Departments of Internal Medicine & Pathology, The Ohio State University, 320 W, 10th Avenue, Columbus, OH 43210, USA ; Comprehensive Cancer Center, The Ohio State University, 320 W, 10th Avenue, Columbus, OH 43210, USA.
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Villalona-Calero
keywords: ALK; BRAF; EGFR; NSCLC; next-generation sequencing; targeted exon capture